ASHP Statement on the Pharmacist's Role in Primary Care

Total Page:16

File Type:pdf, Size:1020Kb

ASHP Statement on the Pharmacist's Role in Primary Care 368 Medication Therapy and Patient Care: Specific Practice Areas–Statements ASHP Statement on the Pharmacist’s Role in Primary Care Position The purposes of this statement are to promote under- standing of the various ways in which pharmacists provide or The American Society of Health System Pharmacists contribute to the provision of primary care in integrated health (ASHP) believes that pharmacists have a role in meeting the systems and to clarify future directions for pharmacists in primary care needs of patients by fulfilling their responsi- efforts to expand patient care services in primary care. bilities to provide pharmaceutical care and, in states where it is authorized, through their expanded responsibilities in Background collaborative drug therapy management. Pharmaceutical care is the direct, responsible provision Changes in the nation’s health care system, especially the of medication-related care for the purpose of achieving definite growth of managed care and integrated health systems, are outcomes that improve a patient’s quality of life.1 Pharmacists stimulating adoption of primary care as a way of meeting establish relationships with patients to ensure the appropriate- basic health care needs and managing access to specialty ness of medication therapy and patients’ understanding of services. Integrated health systems are organized to deliver their therapy, and to monitor the effects of that therapy. In col- acute, intermediate, long-term, home, and ambulatory care. laborative drug therapy management, pharmacists enter agree- They are intended to seamlessly provide care across practice ments with physicians and other prescribers that may authorize settings through appropriate use of individual health profes- 13 pharmacists, for patients who have a confirmed diagnosis, to sionals and teams. Integrated systems offer opportunities select appropriate medication therapies and regimens and for pharmacists and other health care providers to detect adjust them on the basis of patients’ responses. and respond to the medication-related needs of patients in National and international organizations, states, and transition between settings (e.g., from inpatient to ambulatory health care organizations, among others, may have differing care). As integrated systems expand to offer more intensive or overlapping definitions of primary care. Primary care is ambulatory care services and cover broader geographic areas, a concept intended to improve the quality of care received primary care will become more prominent. Improving patients’ by everyone in the United States.2 For the purposes of this access to and continuity of care, implementing disease manage- document, primary care is defined as the provision of inte- ment, and focusing on quality-related outcomes contribute to 14 grated, accessible health care services by clinicians who are optimizing drug costs within the total costs of patient care. accountable for addressing a majority of personal health care Pharmacists involved in primary care contribute to all of these. needs, developing a sustained partnership with patients, and Pharmacists participate in primary care services in a practicing in the context of family and community. Primary variety of practice settings within integrated health systems, care services should be comprehensive, coordinated, and including the acute (inpatient), physician office, clinic, phar- continuously provided over time by individuals or a team macy, long-term, and home settings. A growing number of of health care professionals according to the patient’s needs. acute care hospitals have pharmacists participating in patient Services should be accessible to patients by telephone or at care activities in ambulatory care clinics and hospital-based sites of care provision. Clinicians who provide these services home health care services.15 Along with other providers, are responsible for the quality of care, the satisfaction of pharmacists are expanding and further defining practice patients, and the efficient use of resources, as well as for models to meet the pharmaceutical and primary care needs their own ethical behavior.3 of patients throughout the continuum of care. Practice elements of pharmaceutical care and collabora- tive drug therapy management are consistent with the intents Responsibilities and evolving forms of primary care. ASHP supports the development of definitions and working models of primary Pharmacists involved in primary care participate with other care that recognize and incorporate the services of pharmacists team members in the management of patients for whom medi- for meeting primary care needs of patients. In general, phar- cations are a focus of therapy. Pharmacists’ responsibility is to macists contribute to the provision of primary care through the optimize patients’ medication therapy. Primary care pharmaceu- delivery of pharmaceutical care and in collaboration with other tical services should be designed to support the various compo- health care providers.4–9 Furthermore, pharmacists may directly nents of the medication-use process (ordering, dispensing, ad- provide a limited range of primary care functions in addition to ministering, monitoring, and educating) as individual steps or as those encompassed by pharmaceutical care, either indepen- they relate to one another in the continuum of care. Pharmacists dently or in collaboration with other members of a primary care should evaluate all components of the medication-use process team.10,11 High-quality, coordinated, and continuous medication to optimize the potential for positive patient outcomes. management for patients should be measurable as a result of the provision of pharmaceutical care within a primary care de- Functions. In general, pharmacists who participate in livery model. The benefits to patients are valuable access to providing primary care to individual patients perform the medication information, the prevention and resolution of med- following functions in collaboration with physicians and ication-related problems, improved outcomes, and increased other members of the primary care team: satisfaction.12 Pharmacists are able to use medication-related encounters with patients to provide information and either • Perform patient assessment for medication-related resolve or make a referral for other health care needs. factors. Medication Therapy and Patient Care: Specific Practice Areas–Statements 369 • Order laboratory tests necessary for monitoring include counseling (e.g., abuse of alcohol, tobacco, and other outcomes of medication therapy. drugs; use of seat belts) and ordering screening procedures • Interpret data related to medication safety and (e.g., blood lipids and glucose, fecal occult blood). The com- effectiveness. plexity of services provided varies according to patient need • Initiate or modify medication therapy care plans on the and support from within the integrated health system. basis of patient responses. Areas of primary care pharmacy practice that have • Provide information, education, and counseling to previously been demonstrated to be cost-effective and to improve patients about medication-related care. outcomes include participation on primary care teams and • Document the care provided in patients’ records. primary care clinics for medication monitoring and refill in • Identify any barriers to patient compliance. the management of general or specific pharmacotherapy (e.g., • Participate in multidisciplinary reviews of patients’ for asthma, hypertension, dyslipidemia, anticoagulation, progress. dermatologic diseases, diabetes, and psychotherapeutics).16–23 • Communicate with payers to resolve issues that may impede access to medication therapies. Documentation of Pharmacists’ Care. Pharmacists in each • Communicate relevant issues to physicians and other setting should routinely document the quantity and qual- team members. ity of services provided and the estimated effect on patient outcomes. Pharmacists must safeguard patients’ rights to Expanded Functions. Expanded primary care functions of privacy and confidentiality. Patient information should be pharmacists include all the functions previously described shared only with members of the health care team and others as well as: with authorized access as needed for the care of patients. Methods for referral to other health care providers and • Provide individualized health promotion and disease documentation of care provided should be defined and must prevention, including administration of immunizations occur as a routine part of the daily functions of a pharma- where this is legally and organizationally authorized. cist’s practice. When more than one pharmacist is involved • Perform limited physical assessment and supervise in delivering care, practice standards for the group should medication therapy with appropriate collaborative be adopted and should serve as a guide for all. Pharmacists drug therapy management authority. must also establish methods of communication among them- selves in order to provide and ensure continuity of pharma- Pharmacists’ Scope of Practice. The pharmacist may have a ceutical care on behalf of patients served. range of practice privileges that vary in their extent of authority and responsibility. Pharmacists who participate in collaborative Value of Pharmacist’s Care. Methods for obtaining compen- primary care practice should meet the health care organization’s sation or economic and professional credit for value-added competency requirements
Recommended publications
  • Immunology New Orleans, LA Toll Free 888.355.4191 Toll Free Fax 888.355.4192 Krogerspecialtypharmacy.Com
    Immunology New Orleans, LA toll free 888.355.4191 toll free fax 888.355.4192 krogerspecialtypharmacy.com Need By Date: _________________________________________________ Ship To: Patient Office Fax Copy: Rx Card Front/Back Clinical Notes Medical Card Front/Back Patient Information Prescriber Information Patient Name Prescriber Name Address Address City State Zip City State Zip Main Phone Alternate Phone Phone Fax Social Security # Contact Person Date of Birth Male Female DEA # NPI # License # Clinical Information Diagnosis: J45.40 Moderate Asthma J45.50 Severe Asthma L20.9 Atopic Dermatitis L50.1 Chronic Idiopathic Urticaria (CIU) Eosinophil Levels J33 Chronic Rhinosinusitis with Nasal Polyposis Other: ________________________________ Dx Code: ___________ Drug Allergies Concomitant Therapies: Short-acting Beta Agonist Long-acting Beta Agonist Antihistamines Decongestants Immunotherapy Inhaled Corticosteroid Leukotriene Modifiers Oral Steroids Nasal Steroids Other: _____________________________________________________________ Please List Therapies Weight kg lbs Date Weight Obtained Lab Results: History of positive skin OR RAST test to a perennial aeroallergen Pretreatment Serum lgE Level: ______________________________________ IU per mL Test Date: _________ / ________ / ________ MD Specialty: Allergist Dermatologist ENT Pediatrician Primary Care Prescription Type: Naïve/New Start Restart Continued Therapy Pulmonologist Other: _________________________________________ Last Injection Date: _________ / ________
    [Show full text]
  • Clinical Pharmacy Specialist
    SAMPLE JOB DESCRIPTION Clinical Pharmacist Specialist I. JOB SUMMARY The Clinical Pharmacist Specialists are responsible and accountable for the provision of safe, effective, and prompt medication therapy. Through various assignments within the department, they provide support of centralized and decentralized medication-use systems as well as deliver optimal medication therapy to patients with a broad range of disease states. Clinical Pharmacist Specialists proficiently provide direct patient-centered care and integrated pharmacy operational services in a decentralized practice setting with physicians, nurses, and other hospital personnel. These clinicians are aligned with target interdisciplinary programs and specialty services to deliver medication therapy management within specialty patient care services and to ensure pharmaceutical care programs are appropriately integrated throughout the institution. In these clinical roles, Clinical Pharmacist Specialists participate in all necessary aspects of the medication-use system while providing comprehensive and individualized pharmaceutical care to the patients in their assigned areas. Pharmaceutical care services include but are not limited to assessing patient needs, incorporating age and disease specific characteristics into drug therapy and patient education, adjusting care according to patient response, and providing clinical interventions to detect, mitigate, and prevent medication adverse events. Clinical Pharmacist Specialists serve as departmental resources and liaisons to other
    [Show full text]
  • Patient Care Through Telepharmacy September 2016
    Patient Care through Telepharmacy September 2016 Gregory Janes Objectives 1. Describe why telepharmacy started and how it has evolved with technology 2. Explain how telepharmacy is being used to provide better patient care, especially in rural areas 3. Understand the current regulatory environment around the US and what states are doing with regulation Agenda ● Origins of Telepharmacy ● Why now? ● Telepharmacy process ● Regulatory environment ● Future Applications Telepharmacy Prescription verification CounselingPrescription & verification Education History Origins of Telepharmacy 1942 Australia’s Royal Flying Doctor Service 2001 U.S. has first state pass telepharmacy regulation 2003 Canada begins first telepharmacy service 2010 Hong Kong sees first videoconferencing consulting services US Telepharmacy Timeline 2001 North Dakota first state to allow 2001 Community Health Association in Spokane, WA launches program 2002 NDSU study begins 2003 Alaska Native Medical Center program 2006 U.S. Navy begins telepharmacy 2012 New generation begins in Iowa Question #1 What was the first US state to allow Telepharmacy? a) Alaska b) North Dakota c) South Dakota d) Hawaii Question #1 What was the first US state to allow Telepharmacy? a) Alaska b) North Dakota c) South Dakota d) Hawaii NDSU Telepharmacy Study Study from 2002-2008 ● 81 pharmacies ○ 53 retail and 28 hospital ● Rate of dispensing errors <1% ○ Compared to national average of ~2% ● Positive outcomes, mechanisms could be improved Source: The North Dakota Experience: Achieving High-Performance
    [Show full text]
  • STEM Disciplines
    STEM Disciplines In order to be applicable to the many types of institutions that participate in the HERI Faculty Survey, this list is intentionally broad and comprehensive in its definition of STEM disciplines. It includes disciplines in the life sciences, physical sciences, engineering, mathematics, computer science, and the health sciences. Agriculture/Natural Resources Health Professions 0101 Agriculture and related sciences 1501 Alternative/complementary medicine/sys 0102 Natural resources and conservation 1503 Clinical/medical lab science/allied 0103 Agriculture/natural resources/related, other 1504 Dental support services/allied 1505 Dentistry Biological and Biomedical Sciences 1506 Health & medical administrative services 0501 Biochem/biophysics/molecular biology 1507 Allied health and medical assisting services 0502 Botany/plant biology 1508 Allied health diagnostic, intervention, 0503 Genetics treatment professions 0504 Microbiological sciences & immunology 1509 Medicine, including psychiatry 0505 Physiology, pathology & related sciences 1511 Nursing 0506 Zoology/animal biology 1512 Optometry 0507 Biological & biomedical sciences, other 1513 Osteopathic medicine/osteopathy 1514 Pharmacy/pharmaceutical sciences/admin Computer/Info Sciences/Support Tech 1515 Podiatric medicine/podiatry 0801 Computer/info tech administration/mgmt 1516 Public health 0802 Computer programming 1518 Veterinary medicine 0803 Computer science 1519 Health/related clinical services, other 0804 Computer software and media applications 0805 Computer systems
    [Show full text]
  • Pharmacotherapy-Enhancing Drugs
    EDITORIAL NOTE Pharmacotherapy-Enhancing drugs Robin Karli* Karli R. Pharmacotherapy-Enhanced drugs. Clin Pharmacol Toxicol Res. 2021;4(2):1. DESCRIPTION Pharmacotherapy is related to several diseases and disorders. The medication varies from one disease or disorder to the other. Pharmacotherapy is provided to diseases and disorders related to Cardiovascular, respiratory, n the treatment of addiction, medications are wanted to reduce the gastrointestinal, renal, neurological, psychiatric, endocrinologic, gynecologic I intensity of withdrawal symptoms, reduce alcohol and other drug craving and obstetric, urological, immunologic, rheumatologic, ophthalmic, and reduce the likelihood of use or relapse for specific drugs by blocking dermatologic, hematologic, infectious diseases, oncologic and nutritional their effect. The primary goal of medication-assisted treatment is for the disorders. patient to achieve fully-sustained remission. SELECTION OF AN ANTIDEPRESSANT MEDICATION Pharmacotherapy is therapy using pharmaceutical drugs, as distinguished from therapy using surgery (surgical therapy), radiation (radiation therapy), movement (physical therapy), or other modes. Among The overall effectiveness of antidepressant medications is usually equivalent between and within classes of medicines. However, there are distinct physicians, sometimes the term medical therapy refers specifically to differences in individual patient response to and side effects caused by the pharmacotherapy as against surgical or other therapy; as an example, in classes of medicines and individual agents. The genetic differences within the oncology, medical oncology is thus distinguished from surgical oncology. metabolism of certain medications including antidepressants are often Pharmacists are experts in pharmacotherapy and are liable for ensuring determined by cytochrome P450 genetic testing. This testing may identify the safe, appropriate, and economical use of pharmaceutical drugs.
    [Show full text]
  • Preventive Health Care
    PREVENTIVE HEALTH CARE DANA BARTLETT, BSN, MSN, MA, CSPI Dana Bartlett is a professional nurse and author. His clinical experience includes 16 years of ICU and ER experience and over 20 years of as a poison control center information specialist. Dana has published numerous CE and journal articles, written NCLEX material, written textbook chapters, and done editing and reviewing for publishers such as Elsevire, Lippincott, and Thieme. He has written widely on the subject of toxicology and was recently named a contributing editor, toxicology section, for Critical Care Nurse journal. He is currently employed at the Connecticut Poison Control Center and is actively involved in lecturing and mentoring nurses, emergency medical residents and pharmacy students. ABSTRACT Screening is an effective method for detecting and preventing acute and chronic diseases. In the United States healthcare tends to be provided after someone has become unwell and medical attention is sought. Poor health habits play a large part in the pathogenesis and progression of many common, chronic diseases. Conversely, healthy habits are very effective at preventing many diseases. The common causes of chronic disease and prevention are discussed with a primary focus on the role of health professionals to provide preventive healthcare and to educate patients to recognize risk factors and to avoid a chronic disease. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 1 Policy Statement This activity has been planned and implemented in accordance with the policies of NurseCe4Less.com and the continuing nursing education requirements of the American Nurses Credentialing Center's Commission on Accreditation for registered nurses. It is the policy of NurseCe4Less.com to ensure objectivity, transparency, and best practice in clinical education for all continuing nursing education (CNE) activities.
    [Show full text]
  • A Tool to Help Clinicians Do What They Value Most
    Health Information Technology: a Tool to Help Clinicians Do What They Value Most Health care professionals like you play a vital role in improving the health outcomes, quality of care, and the health care experience of patients. Health information technology (health IT) is an important tool that you can use to improve clinical practice and the health of your patients. Health IT can help health care professionals to do what you do best: provide excellent care to your patients. Research shows that when patients are Health IT encompasses a wide range of electronic tools that can help you: engaged in their health care, it can lead to • Access up-to-date evidence-based clinical guidelines and decision measurable improvements in safety and support quality. • Improve the quality of care and safety of your patients Source: Agency for Healthcare Research and Quality (AHRQ) • Provide proactive health maintenance for your patients • Better coordinate patients’ care with other providers through the secure and private sharing of clinical information. Health IT can help you to solve clinical problems with real-time data Quality improvement and clinical decision support rely on information about your patient population being readily available in digital form. Health IT can help you monitor your patients’ health status and make specific and targeted recommendations to improve your patients’ health. Access to real-time data through electronic health records and health IT will help you: A MAJORITY OF PROVIDERS • Use clinical decision support to highlight care options tailored to believe that electronic health information your patients has the potential to improve the quality of patient care and care coordination.
    [Show full text]
  • Pharmacist-Physician Team Approach to Medication-Therapy
    Pharmacist-Physician Team Approach to Medication-Therapy Management of Hypertension The following is a synopsis of “Primary-Care-Based, Pharmacist-Physician Collaborative Medication-Therapy Management of Hypertension: A Randomized, Pragmatic Trial,” published online in June 2014 in Clinical Therapeutics. What is already known on this topic? found that the role of the pharmacist differed within each study; whereas some pharmacists independently initiated and High blood pressure, also known as hypertension, is a changed medication therapy, others recommended changes major risk factor for cardiovascular disease, the leading to physicians. Pharmacists were already involved in care in all cause of death for U.S. adults. Helping patients achieve but one study. blood pressure control can be difficult for some primary care providers (PCPs), and this challenge may increase with After reviewing the RCTs, the authors conducted a randomized the predicted shortage of PCPs in the United States by 2015. pragmatic trial to investigate the processes and outcomes that The potential shortage presents an opportunity to expand result from integrating a pharmacist-physician team model. the capacity of primary care through pharmacist-physician Participants were randomly selected to receive PharmD-PCP collaboration for medication-therapy management (MTM). MTM or usual care from their PCPs. The authors conducted MTM performed through a collaborative practice agreement the trial within a university-based internal medicine medical allows pharmacists to initiate and change medications. group where the collaborative PharmD-PCP MTM team Researchers have found positive outcomes associated included an internal medicine physician and two clinical with having a pharmacist on the care team; however, the pharmacists, both with a Doctor of Pharmacy degree, at least evidence is limited to only a few randomized controlled 1 year of pharmacy practice residency training, and more than trials (RCTs).
    [Show full text]
  • Patient Safety Clinical Pharmacy Collaborative (PSPC) Guidebook
    GUIDEBOOK Planning and Implementing a Successful Collaborative in a Rural Area How the Eastern Virginia Medical School (EVMS) Patient Safety and Clinical Pharmacy Services Collaborative is changing Pharmacy Services in the Eastern Virginia ACKNOWLEDGEMENTS Thank you to the many people who contributed to this document. We acknowledge the Eastern Virginia Medical School Patient Safety and Clinical Pharmacy Services Collaborative members who initiated the development of this document. Thank you to the participant organizations’ leadership members who consistently supported these efforts. The following individuals provided extensive time, effort and dedication to the development of this document: Judy Wessell Judy A. Wessell MSN, APRN, BC, ACRN, AACRN, AAHIVS. Ms. Wessell has been an HIV Nurse Practitioner for 13 years and a Registered Nurse for greater than 36 years. She received her diploma of Nursing from the Newport Hospital School of Nursing in Newport, RI, her BSN and MSN at Old Dominion University, Norfolk, VA. Ms. Wessell is currently the Nurse Practitioner Supervisor at the Eastern Virginia Medical School (EVMS), Center for Care of Immune Deficiency (C3ID), Infectious Disease Clinic. She is an HIV Health Educator with the EVMS AIDS Resource and Consultation Center, providing professional and community educational programs. She is a member of the quality improvement committee and a member of the EVMS Patient Safety and Clinical Pharmacy Collaborative. Tanya Kearney Tanya K. Kearney, MPA, has eight years of experience as Director for the AIDS Resource Center at Eastern Virginia Medical School. She works with health care providers, community- based AIDS service organizations, government agencies, professional associations and academic and community health care providers, to offer multidisciplinary educational programs on HIV/AIDS and other related topics.
    [Show full text]
  • Current Practices of Obesity Pharmacotherapy, Bariatric Surgery Referral and Coding for Counselling by Healthcare Professionals Christine Petrin, Scott Kahan, M
    Obesity Science & Practice doi: 10.1002/osp4.53 ORIGINAL ARTICLE Current practices of obesity pharmacotherapy, bariatric surgery referral and coding for counselling by healthcare professionals Christine Petrin, Scott Kahan, M. Turner, C. Gallagher and W. H. Dietz George Washington University, Summary Washington, DC, USA Introduction Received 21 April 2016; revised 7 June 2016; accepted 9 June 2016 Rates of obesity pharmacotherapy use, bariatric surgery and intensive behavioural counselling have been extremely low. Address for correspondence: C Petrin, Objectives George Washington University, 950 New Hampshire Ave NW Suite 300, Washington, DC 20037, USA. E-mail: cepetrin@gwmail. The primary objective of this study was to survey healthcare provider beliefs, practice gwu.edu and knowledge regarding obesity management. Methods Primary care physicians (PCPs), OB-GYN physicians and nurse practitioners (NPs) responded to a web-based survey related to drug therapy practice, bariatric surgery referral and reimbursement coding practice. Results Rates of reported use of obesity pharmacotherapy appear to be increasing among PCPs, which is likely related to the approval of four new obesity pharmacotherapy agents since 2012. Rates of pharmacotherapy use among OB-GYNs and NPs appear much lower. Similarly, few PCPs are averse to recommending bariatric surgery, but aversion among OB-GYNs and NPs is significantly higher. Conclusion Together, these observations suggest that OB-GYN and NP populations are important targets for education about obesity management. Very few PCPs, OB-GYNs or NPs use behavioural counselling coding for obesity. Better understanding of why this benefit is not being fully used could inform outreach to improve counselling rates. Keywords: Bariatric surgery referral, CPT coding, obesity counselling, obesity pharmacotherapy.
    [Show full text]
  • Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®)
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) Policy Number: 2021D0088F Effective Date: July 1, 2021 Instructions for Use Table of Contents Page Community Plan Policy Coverage Rationale ....................................................................... 1 • Intravenous Iron Replacement Therapy (Feraheme®, Definitions ...................................................................................... 3 Injectafer®, & Monoferric®) Applicable Codes .......................................................................... 3 Background.................................................................................... 4 Benefit Considerations .................................................................. 4 Clinical Evidence ........................................................................... 5 U.S. Food and Drug Administration ............................................. 7 Centers for Medicare and Medicaid Services ............................. 8 References ..................................................................................... 8 Policy History/Revision Information ............................................. 9 Instructions for Use ....................................................................... 9 Coverage Rationale See Benefit Considerations This policy refers to the following intravenous iron replacements: Feraheme® (ferumoxytol) Injectafer® (ferric carboxymaltose) Monoferric® (ferric derisomaltose)* The following
    [Show full text]
  • Study Guide Medical Terminology by Thea Liza Batan About the Author
    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
    [Show full text]